Literature DB >> 2470786

Human immunodeficiency virus infection of helper T cell clones. Early proliferative defects despite intact antigen-specific recognition and interleukin 4 secretion.

J Laurence1, S M Friedman, E K Chartash, M K Crow, D N Posnett.   

Abstract

HIV selectively inhibited the proliferative response of clonal CD4+ T lymphocytes to alloantigen while other alloantigen-dependent responses were unperturbed. Specifically, impaired blastogenesis could be dissociated from alloantigen-specific induction of the B cell activation molecule CD23, IL-4 release, and inositol lipid hydrolysis. In addition, membrane expression of pertinent T cell receptor molecules, including CD2, CD3, and T cell antigen receptor (Ti), remained intact. Using two MHC class II-specific human CD4+ helper T cell clones, the proliferative defect was shown to be an early consequence of HIV infection, occurring within 4 d of viral inoculation and preceding increases in mature virion production. It was generalizable to three distinct methods of T cell activation, all independent of antigen-presenting cells: anti-CD3 mediated cross-linking of the CD3/Ti complex; anti-CD2 and phorbol 12-myristic 13-acetate (PMA); and anti-CD28 plus PMA. These abnormalities were not mitigated by addition of exogenous IL-2, even though expression of the IL-2 receptor (CD25) was unaltered. These studies define a selective blockade in T cell function early after HIV exposure that could serve as a model for certain in vivo manifestations of AIDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470786      PMCID: PMC303904          DOI: 10.1172/JCI114090

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.

Authors:  P A Luciw; C Cheng-Mayer; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

2.  Phosphorylation of the rev gene product of human immunodeficiency virus type 1.

Authors:  J Hauber; M Bouvier; M H Malim; B R Cullen
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

3.  Cloned allospecific human helper T cell lines induce an MHC-restricted proliferative response by resting B cells.

Authors:  D Goldberg; A Green; A B Gottlieb; M K Crow; A Lewison; S M Friedman
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

4.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

5.  Tumor promoter, TPA, enhances replication of HTLV-III/LAV.

Authors:  S Harada; Y Koyanagi; H Nakashima; N Kobayashi; N Yamamoto
Journal:  Virology       Date:  1986-10-30       Impact factor: 3.616

6.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.

Authors:  R J Robb; W C Greene; C M Rusk
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

7.  Soluble suppressor factors in patients with acquired immune deficiency syndrome and its prodrome. Elaboration in vitro by T lymphocyte-adherent cell interactions.

Authors:  J Laurence; A B Gottlieb; H G Kunkel
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

8.  Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity.

Authors:  J Laurence; A Saunders; J Kulkosky
Journal:  Science       Date:  1987-03-20       Impact factor: 47.728

9.  Functionally restricted, allospecific, human helper T cell lines that amplify either B cell or cytolytic T cell responses.

Authors:  S M Friedman; G S Thompson
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

10.  Direct T helper-B cell interactions induce an early B cell activation antigen.

Authors:  M K Crow; J A Jover; S M Friedman
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  9 in total

1.  The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania.

Authors:  P Mayaud; D K Gill; H A Weiss; E Uledi; L Kopwe; J Todd; G ka-Gina; H Grosskurth; R J Hayes; D C Mabey; C J Lacey
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

2.  Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

Authors:  C C Wilson; B Palmer; S Southwood; J Sidney; Y Higashimoto; E Appella; R Chesnut; A Sette; B D Livingston
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement.

Authors:  J Laurence; A Saunders; E Early; J E Salmon
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

4.  Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Authors:  R J Trauger; W K Giermakowska; F Ferre; P C Duffy; M R Wallace; D E Lewis; H J Beecham; K G Burnett; F C Jensen; D J Carlo
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

5.  Human immunodeficiency virus induction of malignant transformation in human B lymphocytes.

Authors:  J Laurence; S M Astrin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

6.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

7.  Human immunodeficiency virus Tat induces functional unresponsiveness in T cells.

Authors:  N Chirmule; S Than; S A Khan; S Pahwa
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.

Authors:  Kendall A Smith; Sofija Andjelic; Zoran Popmihajlov; Liza Kelly-Rossini; Aquanette Sass; Martin Lesser; Steven Benkert; Cory Waters; Joyce Ruitenberg; Paul Bellman
Journal:  PLoS Clin Trials       Date:  2007-01-26

9.  Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva.

Authors:  R Crombie; R L Silverstein; C MacLow; S F Pearce; R L Nachman; J Laurence
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.